FDA 483 - J. John Mann, M.D. - December 05, 2023

An FDA inspection of New York State Psychiatric Institute, a Sponsor-Investigator, revealed a significant deviation from an investigational plan. The firm failed to conduct an investigation in accordance with the signed statement of investigator and protocol requirements. Specifically, a substantial number of subjects did not have required weekly assessments completed during a critical phase of the study.